Results for pharma ip
Thinking beyond the sequence: CAR-T cell therapy litigation at the UPC (2seventy bio v Johnson & Johnson, UPC_CFI_029/2026) Thinking beyond the sequence: CAR-T cell therapy litigation at the UPC (2seventy bio v Johnson & Johnson, UPC_CFI_029/2026) Reviewed by Dr Rose Hughes on Monday, August 17, 2026 Rating: 5
Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell) Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell) Reviewed by Dr Rose Hughes on Sunday, March 29, 2026 Rating: 5
The validity and value of cell therapy safety protocol inventions (T 1555/23) The validity and value of cell therapy safety protocol inventions (T 1555/23) Reviewed by Dr Rose Hughes on Friday, February 27, 2026 Rating: 5
A new way to define T cells and what it means for cell therapy IP A new way to define T cells and what it means for cell therapy IP Reviewed by Dr Rose Hughes on Monday, January 19, 2026 Rating: 5
EPO pharma case law trends 2025: Clinical inventions EPO pharma case law trends 2025: Clinical inventions Reviewed by Dr Rose Hughes on Monday, November 24, 2025 Rating: 5
The reproducibility challenge for advanced therapies (T 0827/23) The reproducibility challenge for advanced therapies (T 0827/23) Reviewed by Dr Rose Hughes on Monday, August 04, 2025 Rating: 5
Why patents matter: Understanding the importance of IP in the pharma industry Why patents matter: Understanding the importance of IP in the pharma industry Reviewed by Dr Rose Hughes on Wednesday, July 23, 2025 Rating: 5
Powered by Blogger.